American Century Entities Disclose Over 5% Ownership in QuidelOrtho as of September 30, 2026
A recent Schedule 13G filing reveals that American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research each reported beneficial ownership stakes in QuidelOrtho Corporation common stock as of September 30, 2026. American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research each reported ownership of 3,926,634 shares (5.7%), while American Century ETF Trust reported 3,782,204 shares (5.5%). The filing indicates these securities were acquired and are held in the ordinary course of business, not to influence control of the issuer.
QuidelOrtho (QDEL) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky, LLP has announced an investigation into QuidelOrtho Corporation (NASDAQ: QDEL) following a significant 14% drop in share price. This decline occurred after the company reported a 45% decrease in China revenue and a 39% decrease in respiratory revenue for the third quarter of 2026. The firm is encouraging investors who suffered losses to come forward for a no-cost loss review.
Law firm investigates QuidelOrtho officers for possible shareholder rights breaches
Halper Sadeh LLC is investigating whether certain officers and directors of QuidelOrtho Corporation violated their fiduciary duties to shareholders, with long-term shareholders potentially eligible for corporate governance reforms or financial relief. The firm offers free consultations and works on a contingent fee basis, urging shareholders to act quickly due to potential time limits on enforcing their rights. This investigation comes amidst a mixed performance in the health sector, as indicated by Pluang's market data.
Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. The firm is encouraging long-term shareholders to contact them to discuss potential legal rights and options, including corporate governance reforms, the return of funds to the company, or other relief. This investigation aims to enhance shareholder value through improved company policies and oversight.
QuidelOrtho launches VITROS 450 waterless chemistry testing for low-volume laboratories
QuidelOrtho Corporation has launched the VITROS 450 Chemistry System in key global markets, offering a compact, waterless analyzer for low-volume and community-based laboratories. This system utilizes MicroSlide™ technology to provide high-quality, reliable chemistry testing, particularly benefiting settings with limited water, space, or staffing. The launch aims to advance diagnostic access and quality across diverse healthcare environments by offering a sustainable and user-friendly solution.
What Has Changed For QuidelOrtho Since Its 60% Fall
QuidelOrtho's shares have fallen 60% in 2026 due to weak respiratory testing demand and policy worries. The company is addressing its balance sheet by exploring a US$1.5 billion sale of its point-of-care unit, which aligns with a cautious view focused on debt and cost pressure. While Q3 2026 revenue declined, net margin improved, and analysts believe cost cuts and cash generation efforts can reshape the company's future, assuming management delivers on sustained margin and free cash flow improvement.
QDEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving QuidelOrtho
SueWallSt has initiated an investigation into QuidelOrtho (NASDAQ: QDEL) after its shares dropped approximately 14% following a 45% decline in China revenue for the third quarter of 2026. This decline contradicts the company's May 2026 statement that China's volume-based procurement program would not materially impact total annualized revenue. The investigation aims to determine if QuidelOrtho failed to adequately disclose risks related to China's regulatory pricing environment, potentially leading to securities law violations.
Form 8K QuidelOrtho Corp For: 3 November By Investing.com
This article from Investing.com announces that QuidelOrtho Corp filed a Form 8K on November 3, 2026. The filing is a standard disclosure for significant events that shareholders should know about, though the specific details of this particular 8K are not provided within the article. It notes the stock symbol QDEL and includes market data and related news.
QuidelOrtho Targets More Than $80 Million in 2027 Savings
QuidelOrtho Corporation announced a restructuring program aimed at achieving over $80 million in annual savings by 2027, despite an 11.6% year-over-year decline in third-quarter revenue. The company also narrowed its 2026 revenue forecast to $2.52 billion-$2.54 billion and expects $30 million-$35 million in one-time restructuring charges in Q4 2026. This strategic shift will focus on Core Diagnostics and Point of Care Diagnostics to improve profitability and cash flow.
Nine-month cash use rises to $124M as QuidelOrtho (QDEL) posts lower Q3 sales.
QuidelOrtho (QDEL) reported a 12% drop in Q3 2026 revenue to $619 million and a 7% decline in nine-month revenue to $1,869.6 million, primarily due to lower U.S. respiratory sales, the termination of the Grifols Joint Business, and slower distributor sales in China. The company's operating cash use for the nine months increased significantly to $124.0 million from $26.7 million in the prior year. Despite the revenue declines, QuidelOrtho narrowed its nine-month net loss to $238.5 million and launched new cost transformation programs expected to deliver over $80 million in annual savings in 2027.
QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China Destocking ...
QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline in Q3 2026 to $619 million, primarily due to destocking in China and a softer respiratory testing market. The company announced a cost transformation program aimed at over $80 million in annual savings for 2027 and is restructuring into core diagnostics and point-of-care diagnostics to improve focus and profitability. Despite a decline in gross margin and increased net leverage, free cash flow improved significantly to approximately breakeven.
What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call
QuidelOrtho (QDEL) reported a 12% year-over-year revenue decline in Q3 due to China pricing changes and softer respiratory testing demand. The company announced a restructuring program targeting over $80 million in annual savings by 2027 and narrowed its full-year revenue and earnings guidance. Despite challenges, the underlying Labs and Immunohematology businesses showed resilience, and the company plans to reorganize into two distinct businesses: Point of Care Diagnostics and Core Diagnostics.
QuidelOrtho Corp (NASDAQ:QDEL) Q3 2026: EPS Beat, Revenue Miss, and Restructuring Plan
QuidelOrtho Corp (NASDAQ:QDEL) reported mixed Q3 2026 results, with non-GAAP EPS beating consensus but revenue missing expectations. The market reacted negatively, focusing on the revenue shortfall and an 11.6% year-over-year decline in sales, despite the company announcing a restructuring plan aimed at over $80 million in annual savings by 2027. Investors are now watching for revenue stabilization and the scalability of growth in Labs and immunohematology outside China.
QuidelOrtho Q3 2026 Earnings Call Transcript
QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% year-over-year decrease, primarily due to new IVD pricing guidelines in China and a soft respiratory testing market. The company is implementing a new cost transformation and enterprise restructuring program, aiming for over $80 million in annual savings by 2027, and is reorganizing into Core Diagnostics and Point of Care Diagnostics to enhance profitability and focus. Full-year 2026 revenue guidance has been narrowed to $2.52-$2.54 billion, and management remains focused on improving free cash flow and reducing leverage.
Form 8K QuidelOrtho Corp For: 3 November By Investing.com
This article reports that QuidelOrtho Corp filed a Form 8K on November 3, 2026. The Form 8K is a crucial document that companies file with the SEC to announce major events that shareholders should know about. No specific details about the content of the filing are provided in this brief announcement.
QuidelOrtho (QDEL) Expects $80M+ Annual Savings From Restructuring
QuidelOrtho (QDEL) announced a new restructuring program expected to generate over $80 million in annual savings starting in 2027, with one-time charges of $30M–$35M in Q4 2026. The company also narrowed its full-year 2026 guidance and reported that results were impacted by pressures in China and a softer respiratory season. Investors are awaiting detailed guidance and evidence of savings delivery to fully assess the program's impact.
QuidelOrtho (QDEL) Expects $80M+ Annual Savings From Restructuring
QuidelOrtho (QDEL) announced its third-quarter 2026 results and narrowed its full-year guidance. A new restructuring program is projected to yield over $80 million in annual savings starting in 2027, despite incurring $30M–$35M in one-time charges in Q4 2026. These measures are a response to pressures from the China market and a softer respiratory season.
What QuidelOrtho Bears Saw Before A 54% Drop
QuidelOrtho's stock dropped 54% in 2026, prompting an examination of the company's financial health, including its debt and margins. The company is considering selling its point-of-care testing unit for US$1.5 billion to reduce debt and refocus on core diagnostics. Despite improved net margins in Q2 2026, the company still posted a loss, leading to a debate among investors about its future profitability and fair value.
Earnings Preview: QuidelOrtho to Report Financial Results Post-market on November 03
QuidelOrtho (QDEL) is scheduled to release its financial results after the market closes on November 03. Analysts predict the company will report adjusted earnings of $0.94 per share on revenue of $754.67 million for the quarter. Investors will be closely watching for any updates on the company's future guidance.
QuidelOrtho Corporation (QDEL) Stock forecasts
This article provides a brief overview of QuidelOrtho Corporation (QDEL), a company focused on rapid diagnostic testing solutions. It highlights an Argus report on QDEL from October 28, 2026, which includes a current stock price of $13.25 and a price target. The report also mentions the sector as Healthcare and encourages users to upgrade for more detailed insights.
QuidelOrtho Corporation Estimates – NASDAQ:QDEL
This page provides an overview of QuidelOrtho Corporation (NASDAQ: QDEL) financial estimates on TradingView. It allows users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time for both annual and quarterly data.
What Investors Got Wrong About QuidelOrtho Before A 53% Slide
QuidelOrtho's stock price has fallen 53% over the past year despite year-on-year improvements in revenue and net income. Investors had to weigh optimistic and cautious narratives regarding the company's future, with the optimistic view forecasting higher profit margins that the company has yet to achieve. Currently, the stock trades below its selected narrative's fair value, emphasizing the importance of core lab and immunohematology contract growth and margin improvements.
QuidelOrtho Corporation (QDEL) stock price, news, quote and history
QuidelOrtho Corporation (QDEL) stock closed at $14.08, down 0.91%, with significant year-to-date and 1-year returns showing declines of 50.70% and 52.80% respectively. The company, which specializes in diagnostic testing solutions across various medical fields, reported Q2 FY26 revenue of $630.9 million and a net loss of $92.9 million. Analysts currently have an average price target of $14.67, with the latest rating from Citigroup being Neutral.
QuidelOrtho Shares Rise More Than 11% After Friday's 7% Drop
Shares of QuidelOrtho Corporation (QDEL), a global in-vitro diagnostics company, surged over 11% following a 7% drop on Friday. The company is set to release its third-quarter 2026 financial results on November 3.
QuidelOrtho rebounds from recent weakness, jumps 12% (QDEL:NASDAQ)
Shares of QuidelOrtho (QDEL) rallied over 11% on Tuesday, rebounding from recent choppy trading that included a 7% decline last Friday. The stock closed at $14.21, up $1.45. Despite the rally, the company faces financial pressures including high leverage, negative free cash flow, and inventory buildup, with analysts remaining largely bearish due to these concerns and exposure to Chinese pricing reforms.
QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
QuidelOrtho Corporation announced it will release its third quarter 2026 financial results on Tuesday, November 3, 2026, after market close. The company will also host a conference call and webcast to discuss these results at 5:00 p.m. ET on the same day. Interested parties can access the webcast via the investor relations section of QuidelOrtho's website.
J.P. Morgan kept a Sell rating and USD 12.00 target for QuidelOrtho stock
J.P. Morgan maintained a Sell rating and a USD 12.00 price target for QuidelOrtho (QDEL) on October 14, 2026. The company reported Q2 revenue of USD 630.90 million, a 2.00 percent increase year-over-year, and is set to release Q3 results on November 3, 2026. QuidelOrtho's stock was trading at EUR 12.70 on October 20, 2026, with a Nasdaq price of USD 14.25, and faces challenges with declining China revenue while revenue outside China grew.
Form 4 QuidelOrtho Corp: Jonathan Philip Siegrist (EVP of R&D & CTO) For: 15 October
This article reports on a Form 4 filing for QuidelOrtho Corp, specifically detailing a transaction by Jonathan Philip Siegrist, EVP of R&D & CTO, on October 15th. The filing indicates insider trading activity for the company (QDEL), which saw a 9.87% increase in its stock price. The content primarily serves as an announcement of this regulatory filing.
A stock grant vests at QuidelOrtho (QDEL), with 6,695 shares withheld for taxes.
QuidelOrtho's EVP of R&D & CTO, Jonathan Philip Siegrist, acquired 18,657 common shares on October 15, 2026, as a restricted stock unit grant vested. Of these, 6,695 shares were withheld by QuidelOrtho at $13.91 per share to cover tax obligations. An additional 18,657 restricted stock units are set to vest on October 15, 2027.
QuidelOrtho Corporation (QDEL1.MX) insider ownership and holdings
This article details the insider ownership and holdings for QuidelOrtho Corporation (QDEL1.MX). It lists key executives and directors, their most recent transaction type, the date of that transaction, and the number of shares they owned as of that date, based on SEC filings from the last 24 months.
QuidelOrtho stock closed at USD 12.91 on October 16, down 7.19 percent
QuidelOrtho stock (QDEL) closed at USD 12.91 on October 16, 2026, down 7.19 percent on Nasdaq. The company reported second-quarter 2026 revenue of USD 630.90 million and a GAAP net loss of USD 92.90 million. Investors are looking forward to the next estimated earnings date on November 5, 2026, for further financial clarity and a full-year outlook.
Novavax, Ocular Therapeutix, and QuidelOrtho Shares Plummet, What You Need To Know
Shares of Novavax, Ocular Therapeutix, and QuidelOrtho experienced significant drops in an afternoon trading session. This decline is attributed to a broader market sell-off in capital-intensive growth equities, driven by elevated bond yields that reduce market appetite for risk and diminish the present value of future corporate earnings. The article also notes that investors are reassessing the impact of high interest rates on economic growth and corporate debt-servicing capacity, particularly affecting clinical-stage healthcare firms.
QUIDELORTHO CORPORATION (QDEL1.MX) Q2 FY2026 earnings call transcript
QuidelOrtho reported Q2 2026 revenue of $631M, a 2% year-over-year increase in constant currency, though China revenue declined by 23% and respiratory testing was soft. Excluding China, revenue grew 6% and adjusted EBITDA increased 21% to $129M. The company has revised its full-year guidance downwards due to ongoing uncertainty in China's IVD pricing guidelines and a projected muted respiratory season, and has withdrawn its free cash flow guidance.
QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho Corporation announced the grant of equity awards to two new non-executive employees, consisting of restricted stock units (RSUs) for 50,323 shares of common stock. These "Inducement Grants" were approved by the Compensation Committee and are made under the Company's 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over three years, contingent on continued employment.
QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho Corporation announced the grant of equity awards to two newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4). These Inducement Grants consist of restricted stock units (RSUs) for 50,323 shares of common stock, vesting in equal annual installments over three years, contingent on continued employment. The grants are part of the company's 2026 Inducement Plan, exclusively for new hires to attract talent.
J.P. Morgan keeps USD 12.00 target for QuidelOrtho stock, 13.92 percent below price
J.P. Morgan analyst Casey Woodring maintained a Sell rating on QuidelOrtho stock, setting a USD 12.00 price target, which is 13.92 percent below the current Nasdaq price. QuidelOrtho reported second-quarter 2026 revenue of USD 630.90 million and a narrowed net loss of USD 92.90 million. The company is expected to announce its third-quarter 2026 results on November 4, 2026.
QuidelOrtho Reports Q2 2026 Results: Full Earnings Call Transcript
QuidelOrtho reported a 2% increase in total revenue for Q2 2026, with a 6% growth excluding China, and a 21% increase in adjusted EBITDA. The company is commercializing its Nulexa molecular platform, expecting steady growth, but revised its full-year guidance downwards due to ongoing challenges in China and a cautious outlook on the respiratory market. Management is prioritizing improved cash conversion, reduced leverage, and a disciplined approach to capital allocation to strengthen financial performance.
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
QuidelOrtho Corporation (Nasdaq: QDEL) has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. Mr. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research, previously serving at Teva Pharmaceuticals and Genpact. This appointment aims to strengthen the company's communication with the investment community and enhance engagement with shareholders and analysts.
Law firm probes QuidelOrtho officers for possib...
Halper Sadeh LLC is investigating QuidelOrtho Corporation's officers and directors for potential breaches of fiduciary duties to shareholders. The law firm offers free consultations and encourages affected long-term shareholders to seek corporate governance reforms, financial incentives, or other remedies. This investigation aims to enhance company oversight and protect shareholder value, with Pluang's health sector market snapshot showing a bearish trend for most US health stocks on October 8, 2026.
Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact the firm to discuss their rights and options, which may include seeking corporate governance reforms or the return of funds to the company. The firm emphasizes that shareholder involvement can enhance transparency, accountability, and overall shareholder value.
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President, Investor Relations, effective September 28, 2026. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research. This appointment aims to strengthen QuidelOrtho's communication with the investment community and highlight its strategic priorities for long-term value creation.
QuidelOrtho Names Sanjeev Sharma Vice President of Investor Relations
QuidelOrtho Corporation has appointed Sanjeev Sharma, CFA, as Vice President of Investor Relations. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research, previously serving at Teva Pharmaceuticals and Genpact. His role will focus on strengthening engagement with shareholders and analysts and communicating QuidelOrtho's strategy and financial performance.
QuidelOrtho names Sanjeev Sharma as new VP of Investor Relations to boost investor engagement.
QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President of Investor Relations, leveraging his over 20 years of experience to enhance communication with investors and support the company's strategic goals. His appointment, effective September 28, 2026, comes as the company continues to advance its position in the global diagnostics market. The article also notes recent health sector stock performance, including Moderna, Summit Therapeutics, and Cassava Sciences.
QuidelOrtho appoints Sanjeev Sharma as VP of investor relations By Investing.com
QuidelOrtho Corporation has appointed Sanjeev Sharma as its new Vice President of Investor Relations, effective September 28. Sharma brings over two decades of experience in investor relations, corporate strategy, and equity research, having previously held senior roles at Teva Pharmaceuticals and Genpact. He holds a master’s degree in finance and is a Chartered Financial Analyst.
A new executive brings more than 20 years of experience to QuidelOrtho.
QuidelOrtho (QDEL) has appointed Sanjeev Sharma as Vice President of Investor Relations, effective September 28, 2026. Mr. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research, having previously served at Teva Pharmaceuticals and Genpact. His expertise is expected to enhance QuidelOrtho's communications and engagement with shareholders and analysts as the company focuses on long-term value creation.
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
QuidelOrtho Corporation has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research from global organizations like Teva Pharmaceuticals and Genpact. This appointment aims to strengthen QuidelOrtho's engagement with the investment community and clearly communicate its strategic priorities for long-term value creation.
QuidelOrtho stock gained 12.72 percent as debt terms reset
QuidelOrtho's stock (QDEL) rose 12.72% on October 5, 2026, after amending its credit agreement to reset financial covenants through 2029. The company reported a 2.8% increase in second-quarter 2026 revenue but also a GAAP net loss of $92.9 million. Analysts currently have a "Reduce" consensus with an average price target of $13.62.
QuidelOrtho rallies 13% to multi-week high (QDEL:NASDAQ)
QuidelOrtho Corporation (QDEL) shares rallied nearly 13% to close at $12.14 on Monday, marking its highest close since September 10 with notably elevated trading volume. Despite this surge, the stock remains approximately 11% below its 50-day and 32% below its 200-day moving averages. The company recently highlighted its role in global diagnostics by issuing a press release on tools aiding sepsis treatment.
QuidelOrtho (QDEL) Shares Surge 12.7% on October 5, 2026, Amid Elevated Trading Volume
QuidelOrtho (QDEL) shares surged 12.7% on October 5, 2026, accompanied by a significant increase in trading volume, despite the company's deeply discounted Price-to-Sales ratio and ongoing unprofitability. The company's GF Score of 43/100 reflects weak growth and financial strength, though insider buying provides a counterpoint to recent guru trimming. Investors are advised to carefully weigh these mixed signals and monitor future developments.
A Look at QuidelOrtho Corp (QDEL) After 3.8% Gain -- GF Value $3
QuidelOrtho Corp (QDEL) saw a 3.8% stock gain, reaching $10.77, though it remains significantly undervalued according to GuruFocus's GF Value of $33.01. Despite appearing as a possible value trap due to its unprofitability and weak financial strength (2/10), insiders have shown confidence with $1.3 million in share purchases over the last year. The company's GF Score is 43/100, highlighting poor growth and valuation but some competitive advantages.